Share This Page
Suppliers and packagers for ONUREG
✉ Email this page to a colleague
ONUREG
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Bristol | ONUREG | azacitidine | TABLET;ORAL | 214120 | NDA | Celgene Corporation | 59572-730-07 | 7 TABLET, FILM COATED in 1 BLISTER PACK (59572-730-07) | 2020-09-01 |
| Bristol | ONUREG | azacitidine | TABLET;ORAL | 214120 | NDA | Celgene Corporation | 59572-730-14 | 14 TABLET, FILM COATED in 1 BOTTLE (59572-730-14) | 2020-09-01 |
| Bristol | ONUREG | azacitidine | TABLET;ORAL | 214120 | NDA | Celgene Corporation | 59572-740-07 | 7 TABLET, FILM COATED in 1 BLISTER PACK (59572-740-07) | 2020-09-01 |
| Bristol | ONUREG | azacitidine | TABLET;ORAL | 214120 | NDA | Celgene Corporation | 59572-740-14 | 14 TABLET, FILM COATED in 1 BOTTLE (59572-740-14) | 2020-09-01 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Onureg (Azacitidine Tablets)
Introduction
Onureg (azacitidine tablets) is an oral formulation of azacitidine, a hypomethylating agent primarily used to treat adult patients aged 55 and older with specific subtypes of myelodysplastic syndromes (MDS), particularly those who have achieved remission following intensive chemotherapy or hematopoietic stem cell transplantation. Since its approval by the U.S. Food and Drug Administration (FDA) in 2020, Onureg has become a key player in the ongoing management of MDS, emphasizing the vital role of a reliable global supply chain.
This article explores the landscape of suppliers for Onureg, outlining the primary manufacturing entities, their strategic positioning, supply chain considerations, and market dynamics influencing availability.
Manufacturing and Supply Chain Overview
1. Manufacturer of Onureg: Celgene/Bristol-Myers Squibb
The primary supplier of Onureg is Bristol-Myers Squibb (BMS), which acquired Celgene in 2019. The drug was developed and initially commercialized by Celgene, which held the rights prior to the acquisition. As a major biopharmaceutical enterprise, BMS controls the drug’s manufacturing, distribution, and global supply.
2. Production Processes and Raw Material Sourcing
- Active Pharmaceutical Ingredient (API): The core component, azacitidine, is synthesized via complex chemical processes. Large-scale synthesis requires high-purity raw materials and specialized manufacturing facilities.
- Formulation and Tablets: The APIs are formulated into oral tablets under strict Good Manufacturing Practice (GMP) standards. Advanced quality controls are essential to ensure consistency and efficacy.
3. Supply Chain Strategy
- Vertical Integration: BMS maintains integrated manufacturing facilities, often partnering with specialized contract manufacturing organizations (CMOs), to secure supply chain resilience.
- Global Distribution Network: The company leverages an extensive distribution network—covering North America, Europe, Asia Pacific, and emerging markets—to meet global demand.
Key Suppliers and Contractors
1. Contract Manufacturing Organizations (CMOs)
While BMS maintains significant internal manufacturing capabilities, it also depends on numerous CMOs for various components, including APIs and finished dosage manufacturing. Notable CMOs involved in the azacitidine supply chain are:
- CSPC Pharmaceutical Group: A Chinese pharmaceutical company involved in the synthesis and production of critical APIs for oncology agents, potentially collaborating on azacitidine intermediates.
- Fujifilm Diosynth Biotechnologies: Specialized in manufacturing complex APIs under GMP standards, supporting scalable production.
- Other Regional CMOs: Several regional CMOs across North America and Europe provide fill-finish, packaging, and distribution services.
2. Raw Material Suppliers
Critical raw materials for azacitidine synthesis originate from specialized chemical suppliers. These include:
- Global Chemical Suppliers: Companies such as Merck KGaA and Sasol provide precursor chemicals essential for API synthesis.
- Specialized Chemical Manufacturers: Smaller firms specializing in pharmaceutical-grade intermediates contribute to supply chain security.
3. Packaging and Distribution Partners
Post-manufacturing, the packaging is handled by approved vendors aligned with BMS's quality standards, ensuring proper labeling, stability, and regulatory compliance across markets.
Market Dynamics and Supply Considerations
- Manufacturing Complexity: The synthesis of azacitidine involves multi-step chemical processes requiring stringent quality controls, impacting scalability and supply stability.
- Regulatory Compliance: Suppliers must meet global regulatory standards, with inspections and certifications influencing market access.
- Supply Chain Risks: Dependence on regional CMOs and raw material suppliers introduces vulnerabilities related to geopolitical, environmental, or logistical disruptions.
- Global Demand: The increasing prevalence of MDS, aging populations, and the shift towards oral therapies escalate demand, pressuring existing suppliers and prompting supply chain expansions.
Competitive Landscape
Though Bristol-Myers Squibb is the primary supplier, other pharmaceutical companies are developing or have developed competing hypomethylating agents or biosimilars, which could impact future sourcing strategies for Onureg. However, as of now, no approved biosimilar or generic version of azacitidine tablets exists globally, limiting supplier competition.
Future Outlook
- Supply Chain Expansion: BMS is likely investing in expanding its manufacturing footprint and strategic raw material sourcing to accommodate growing demand.
- Partnerships and Collaborations: Strengthening partnerships with CMOs and raw material producers can enhance resilience.
- Potential for Biosimilars or Generics: Regulatory or patent landscape changes could enable entry of competitors, affecting supplier dynamics.
Key Takeaways
- Bristol-Myers Squibb is the sole or primary manufacturer and supplier of Onureg, relying on a complex network of CMOs and raw material providers.
- The production process’s complexity, regulatory standards, and regional logistics are critical factors influencing supply stability.
- The growing global demand for oral MDS therapies underscores the importance of supply chain resilience and capacity expansion.
- Strategic partnerships with specialized CMOs and raw material suppliers are vital for securing consistent supply.
- Future market developments, including biosimilar entries and technological innovations, could reshape supplier structures.
FAQs
1. Who are the main manufacturers of Onureg?
Bristol-Myers Squibb, through its acquisition of Celgene, is the primary manufacturer of Onureg, utilizing internal facilities and partnerships with CMOs for production.
2. Are there alternative suppliers for azacitidine tablets?
Currently, no authorized biosimilars or generic azacitidine tablets are available globally, limiting alternative suppliers for Onureg.
3. What are the major raw materials involved in manufacturing Onureg?
Key raw materials include chemical precursors required for synthetic azacitidine production, sourced from global chemical suppliers specializing in pharmaceutical-grade compounds.
4. How does supply chain complexity affect drug availability?
The multi-step synthesis, strict regulatory standards, and regional manufacturing dependencies can lead to disruptions, impacting consistent drug availability.
5. What future trends could influence the supplier landscape for Onureg?
Expansion of manufacturing capacity, strategic raw material sourcing, potential biosimilar development, and geopolitical factors could significantly influence future supplier dynamics.
References
- U.S. Food and Drug Administration. (2020). FDA approves oral azacitidine for myelodysplastic syndromes.
- Bristol-Myers Squibb. (2022). Onureg (azacitidine tablets) prescribing information.
- industry reports on pharmaceutical supply chains and API manufacturing.
- Pharma intelligence and market analysis reports on hypomethylating agents.
This comprehensive analysis aims to inform pharmaceutical and healthcare professionals, supply chain managers, and investors about Onureg's sourcing landscape to facilitate better strategic decision-making.
More… ↓
